Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase
Identifieur interne : 001B06 ( Istex/Corpus ); précédent : 001B05; suivant : 001B07Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase
Auteurs : Elena N. Klyushnenkova ; Diana V. Kouiavskaia ; James A. Kodak ; Arthur A. Vandenbark ; Richard B. AlexanderSource :
- The Prostate [ 0270-4137 ] ; 2007-07-01.
Abstract
BACKGROUND: The crucial role of CD4 T‐cells in anti‐tumor immune response is widely recognized, yet the identification of HLA class II‐restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T‐cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen (HLA)‐DRB1*1501, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy. METHODS: We immunized transgenic (tg) mice engineered to express HLA‐DRB1*1501 with human PAP. A library of overlapping 20‐mer peptides spanning the entire human PAP sequence was screened in vitro for T‐cell recognition by proliferative and interferon (IFN)‐γ enzyme‐linked immunosorbent spot (ELISPOT) assays. RESULTS: We identified two 20‐mer peptides, PAP (133–152), and PAP (173–192), that were immunogenic and naturally processed from whole PAP in HLA‐DRB1*1501 tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from HLA‐DRB1*1501‐positive patients with GP and normal donors. CONCLUSIONS: These peptides can be used for the design of a new generation of peptide‐based vaccines against prostate cancer. The study can also be helpful in understanding the role of autoimmunity in the development of some forms of chronic prostatitis. Prostate 67: 1019–1028, 2007. © 2007 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/pros.20575
Links to Exploration step
ISTEX:58907371FB3DF76E502B7154DBD5BB13126E1297Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title><author><name sortKey="Klyushnenkova, Elena N" sort="Klyushnenkova, Elena N" uniqKey="Klyushnenkova E" first="Elena N." last="Klyushnenkova">Elena N. Klyushnenkova</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation><affiliation><mods:affiliation>VA Maryland Health Care System, Baltimore, Maryland</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: eklyushnenkova@smail.umaryland.edu</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: University of Maryland School of Medicine, Department of Surgery, 10 S. Pine Street, MSTF, Room 4‐00A, Baltimore, MD 21201.</mods:affiliation></affiliation></author><author><name sortKey="Kouiavskaia, Diana V" sort="Kouiavskaia, Diana V" uniqKey="Kouiavskaia D" first="Diana V." last="Kouiavskaia">Diana V. Kouiavskaia</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Kodak, James A" sort="Kodak, James A" uniqKey="Kodak J" first="James A." last="Kodak">James A. Kodak</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Vandenbark, Arthur A" sort="Vandenbark, Arthur A" uniqKey="Vandenbark A" first="Arthur A." last="Vandenbark">Arthur A. Vandenbark</name><affiliation><mods:affiliation>Department of Neuroimmunology, Portland VA Medical Center, Portland Oregon and Departments of Neurology, and Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon</mods:affiliation></affiliation></author><author><name sortKey="Alexander, Richard B" sort="Alexander, Richard B" uniqKey="Alexander R" first="Richard B." last="Alexander">Richard B. Alexander</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation><affiliation><mods:affiliation>VA Maryland Health Care System, Baltimore, Maryland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:58907371FB3DF76E502B7154DBD5BB13126E1297</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/pros.20575</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-5HZVGH2P-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001B06</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title><author><name sortKey="Klyushnenkova, Elena N" sort="Klyushnenkova, Elena N" uniqKey="Klyushnenkova E" first="Elena N." last="Klyushnenkova">Elena N. Klyushnenkova</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation><affiliation><mods:affiliation>VA Maryland Health Care System, Baltimore, Maryland</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: eklyushnenkova@smail.umaryland.edu</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: University of Maryland School of Medicine, Department of Surgery, 10 S. Pine Street, MSTF, Room 4‐00A, Baltimore, MD 21201.</mods:affiliation></affiliation></author><author><name sortKey="Kouiavskaia, Diana V" sort="Kouiavskaia, Diana V" uniqKey="Kouiavskaia D" first="Diana V." last="Kouiavskaia">Diana V. Kouiavskaia</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Kodak, James A" sort="Kodak, James A" uniqKey="Kodak J" first="James A." last="Kodak">James A. Kodak</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation></author><author><name sortKey="Vandenbark, Arthur A" sort="Vandenbark, Arthur A" uniqKey="Vandenbark A" first="Arthur A." last="Vandenbark">Arthur A. Vandenbark</name><affiliation><mods:affiliation>Department of Neuroimmunology, Portland VA Medical Center, Portland Oregon and Departments of Neurology, and Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon</mods:affiliation></affiliation></author><author><name sortKey="Alexander, Richard B" sort="Alexander, Richard B" uniqKey="Alexander R" first="Richard B." last="Alexander">Richard B. Alexander</name><affiliation><mods:affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</mods:affiliation></affiliation><affiliation><mods:affiliation>VA Maryland Health Care System, Baltimore, Maryland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Prostate</title><title level="j" type="alt">PROSTATE, THE</title><idno type="ISSN">0270-4137</idno><idno type="eISSN">1097-0045</idno><imprint><biblScope unit="vol">67</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1019">1019</biblScope><biblScope unit="page" to="1028">1028</biblScope><biblScope unit="page-count">10</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-01">2007-07-01</date></imprint><idno type="ISSN">0270-4137</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0270-4137</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND: The crucial role of CD4 T‐cells in anti‐tumor immune response is widely recognized, yet the identification of HLA class II‐restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T‐cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen (HLA)‐DRB1*1501, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy. METHODS: We immunized transgenic (tg) mice engineered to express HLA‐DRB1*1501 with human PAP. A library of overlapping 20‐mer peptides spanning the entire human PAP sequence was screened in vitro for T‐cell recognition by proliferative and interferon (IFN)‐γ enzyme‐linked immunosorbent spot (ELISPOT) assays. RESULTS: We identified two 20‐mer peptides, PAP (133–152), and PAP (173–192), that were immunogenic and naturally processed from whole PAP in HLA‐DRB1*1501 tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from HLA‐DRB1*1501‐positive patients with GP and normal donors. CONCLUSIONS: These peptides can be used for the design of a new generation of peptide‐based vaccines against prostate cancer. The study can also be helpful in understanding the role of autoimmunity in the development of some forms of chronic prostatitis. Prostate 67: 1019–1028, 2007. © 2007 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>peptide</json:string><json:string>epitope</json:string><json:string>lymphocyte</json:string><json:string>autoimmune</json:string><json:string>prostatic</json:string><json:string>prostate</json:string><json:string>immunol</json:string><json:string>immunotherapy</json:string><json:string>prostatitis</json:string><json:string>immune</json:string><json:string>prostate cancer</json:string><json:string>phosphatase</json:string><json:string>proliferative</json:string><json:string>immune response</json:string><json:string>klyushnenkova</json:string><json:string>normal donor</json:string><json:string>pbmc</json:string><json:string>allele</json:string><json:string>immunogenic</json:string><json:string>transgenic</json:string><json:string>autologous</json:string><json:string>autoimmunity</json:string><json:string>immunization</json:string><json:string>prostatic acid phosphatase</json:string><json:string>granulomatous prostatitis</json:string><json:string>vaccine</json:string><json:string>assay</json:string><json:string>amino</json:string><json:string>datum</json:string><json:string>chronic prostatitis</json:string><json:string>animal model</json:string><json:string>culture supernatant</json:string><json:string>amino acid</json:string><json:string>prostate cancer patient</json:string><json:string>clinical trial</json:string><json:string>prostate cancer immunotherapy</json:string><json:string>strong response</json:string><json:string>multiple sclerosis</json:string><json:string>line specific</json:string><json:string>myelin oligodendrocyte glycoprotein</json:string><json:string>bare lymphocyte syndrome</json:string><json:string>whole human</json:string><json:string>cancer immunol immunother</json:string><json:string>class peptide</json:string><json:string>prostate antigen</json:string><json:string>clin cancer</json:string><json:string>proliferative assay</json:string><json:string>human lymphocyte culture</json:string><json:string>elispotas describedin thelegend</json:string><json:string>transgenic mouse</json:string><json:string>cancer immunotherapy</json:string><json:string>prostate specific antigen</json:string><json:string>specific peptide</json:string><json:string>autoimmune prostatitis</json:string><json:string>autoimmune disease</json:string><json:string>mouse</json:string><json:string>normal male donor</json:string><json:string>sodium pyruvate</json:string><json:string>autoimmune response</json:string><json:string>tissue culture plate</json:string><json:string>thymidine uptake</json:string><json:string>biotinylated antibody</json:string><json:string>autologous pbmc</json:string><json:string>optimal induction</json:string><json:string>effective immune response</json:string><json:string>protein derivate</json:string><json:string>peripheral blood mononuclear cell</json:string><json:string>similar response</json:string><json:string>lymph node</json:string><json:string>control group</json:string><json:string>peptide library</json:string><json:string>mature human</json:string><json:string>stronger response</json:string><json:string>highest achievable score</json:string><json:string>complete adjuvant</json:string><json:string>interferon immunosorbent spot</json:string><json:string>prostate differentiation antigen</json:string><json:string>immunofluorescence staining</json:string><json:string>tumor destruction</json:string><json:string>autoimmune etiology</json:string><json:string>robust response</json:string><json:string>specific peptide negative control peptide</json:string><json:string>human leukocyte antigen</json:string><json:string>computer algorithm</json:string><json:string>helper epitope</json:string><json:string>autoimmune process</json:string><json:string>peripheral circulation</json:string><json:string>destructive autoimmune process</json:string><json:string>further experiment</json:string><json:string>humanized animal model</json:string><json:string>successful cancer immunotherapy</json:string><json:string>benign prostatic hyperplasia</json:string><json:string>tumor antigen</json:string><json:string>clin immunol</json:string><json:string>crucial role</json:string><json:string>class epitope</json:string><json:string>autologous tumor</json:string><json:string>antigen</json:string></teeft></keywords><author><json:item><name>Elena N. Klyushnenkova</name><affiliations><json:string>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</json:string><json:string>VA Maryland Health Care System, Baltimore, Maryland</json:string><json:string>E-mail: eklyushnenkova@smail.umaryland.edu</json:string><json:string>Correspondence address: University of Maryland School of Medicine, Department of Surgery, 10 S. Pine Street, MSTF, Room 4‐00A, Baltimore, MD 21201.</json:string></affiliations></json:item><json:item><name>Diana V. Kouiavskaia</name><affiliations><json:string>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</json:string></affiliations></json:item><json:item><name>James A. Kodak</name><affiliations><json:string>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</json:string></affiliations></json:item><json:item><name>Arthur A. Vandenbark</name><affiliations><json:string>Department of Neuroimmunology, Portland VA Medical Center, Portland Oregon and Departments of Neurology, and Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon</json:string></affiliations></json:item><json:item><name>Richard B. Alexander</name><affiliations><json:string>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</json:string><json:string>VA Maryland Health Care System, Baltimore, Maryland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>CD4 T lymphocytes</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>DR2 transgenic mice</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HLA‐DR15</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prostate cancer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prostatitis</value></json:item></subject><articleId><json:string>PROS20575</json:string></articleId><arkIstex>ark:/67375/WNG-5HZVGH2P-B</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>BACKGROUND: The crucial role of CD4 T‐cells in anti‐tumor immune response is widely recognized, yet the identification of HLA class II‐restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T‐cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen (HLA)‐DRB1*1501, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy. METHODS: We immunized transgenic (tg) mice engineered to express HLA‐DRB1*1501 with human PAP. A library of overlapping 20‐mer peptides spanning the entire human PAP sequence was screened in vitro for T‐cell recognition by proliferative and interferon (IFN)‐γ enzyme‐linked immunosorbent spot (ELISPOT) assays. RESULTS: We identified two 20‐mer peptides, PAP (133–152), and PAP (173–192), that were immunogenic and naturally processed from whole PAP in HLA‐DRB1*1501 tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from HLA‐DRB1*1501‐positive patients with GP and normal donors. CONCLUSIONS: These peptides can be used for the design of a new generation of peptide‐based vaccines against prostate cancer. The study can also be helpful in understanding the role of autoimmunity in the development of some forms of chronic prostatitis. Prostate 67: 1019–1028, 2007. © 2007 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>9.976</score><pdfWordCount>5470</pdfWordCount><pdfCharCount>37689</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>594 x 792 pts</pdfPageSize><pdfWordsPerPage>547</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>248</abstractWordCount><abstractCharCount>1728</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title><pmid><json:string>17455230</json:string></pmid><genre><json:string>article</json:string></genre><host><title>The Prostate</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1097-0045</json:string></doi><issn><json:string>0270-4137</json:string></issn><eissn><json:string>1097-0045</json:string></eissn><publisherId><json:string>PROS</json:string></publisherId><volume>67</volume><issue>10</issue><pages><first>1019</first><last>1028</last><total>10</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Article</value></json:item><json:item><value>Original Articles</value></json:item></subject></host><namedEntities><unitex><date><json:string>2007</json:string></date><geogName></geogName><orgName><json:string>Lambda, Inc.</json:string><json:string>Department of Neuroimmunology Portland VA Medical Center Portland Oregon and Departments</json:string><json:string>Pierce Biotechnology, Inc.</json:string><json:string>University of Maryland Schoolof Medicine</json:string><json:string>University of Maryland Cancer Center</json:string><json:string>Department of Surgery</json:string><json:string>Science University</json:string><json:string>Millipore, Inc.</json:string><json:string>University of Maryland School of Medicine</json:string><json:string>Wiley-Liss, Inc.</json:string><json:string>Institute</json:string><json:string>American Type Culture Collection, Manassas, VA</json:string><json:string>University of Maryland</json:string><json:string>ICN Biomedicals, Inc.</json:string><json:string>Pierce Biotechnology</json:string><json:string>Wiley-Liss, Inc</json:string><json:string>Cellular Thechnology Ltd., Cleveland</json:string><json:string>Fitzgerald Industries International, Inc.</json:string><json:string>American Red Cross National Histocompatibility Laboratory, University of Maryland</json:string><json:string>University of Washington</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Diana V. Kouiavskaia</json:string><json:string>Arthur A. Vandenbark</json:string><json:string>Pr</json:string><json:string>W. Kwok</json:string><json:string>In</json:string><json:string>Elena N. Klyushnenkova</json:string><json:string>James A. Kodak</json:string><json:string>Oregon Health</json:string><json:string>Richard B. Alexander</json:string></persName><placeName><json:string>IL</json:string><json:string>San Diego</json:string><json:string>Finland</json:string><json:string>Concord</json:string><json:string>Portland</json:string><json:string>Immunogenicity</json:string><json:string>Billerica</json:string><json:string>Turku</json:string><json:string>Seattle</json:string><json:string>Baltimore</json:string><json:string>MD</json:string><json:string>Puri</json:string><json:string>Denmark</json:string><json:string>CA</json:string><json:string>Aurora</json:string><json:string>MA</json:string><json:string>MI</json:string><json:string>Rockford</json:string><json:string>Copenhagen</json:string><json:string>Arlington Heights</json:string><json:string>Detroit</json:string><json:string>OH</json:string><json:string>Canoga Park</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[34]</json:string><json:string>[15,16]</json:string><json:string>[18]</json:string><json:string>[44]</json:string><json:string>[17]</json:string><json:string>[1]</json:string><json:string>[43]</json:string><json:string>[49]</json:string><json:string>Motrich et al. [41]</json:string><json:string>[24,25]</json:string><json:string>[42]</json:string><json:string>Klyushnenkova et al.</json:string><json:string>[48]</json:string><json:string>[35,45,46]</json:string><json:string>[9]</json:string><json:string>[35]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-5HZVGH2P-B</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - urology & nephrology</json:string><json:string>2 - endocrinology & metabolism</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - oncology & carcinogenesis</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Urology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Oncology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/pros.20575</json:string></doi><id>58907371FB3DF76E502B7154DBD5BB13126E1297</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-5HZVGH2P-B/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-5HZVGH2P-B/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-5HZVGH2P-B/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title><title level="a" type="short" xml:lang="en">HLA‐DRB1*1501‐Restricted CD4 T‐Cell Epitopes From Human PAP</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2007 Wiley‐Liss, Inc.</licence></availability><date type="published" when="2007-07-01"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title><title level="a" type="short" xml:lang="en">HLA‐DRB1*1501‐Restricted CD4 T‐Cell Epitopes From Human PAP</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Elena N.</forename><surname>Klyushnenkova</surname></persName><email>eklyushnenkova@smail.umaryland.edu</email><affiliation><orgName type="department">Division of Urology</orgName><orgName type="institution">University of Maryland School of Medicine</orgName><address><addrLine>Baltimore</addrLine><addrLine>Maryland</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation><affiliation><address><addrLine>VA Maryland Health Care System</addrLine><addrLine>Baltimore, Maryland</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Diana V.</forename><surname>Kouiavskaia</surname></persName><affiliation><orgName type="department">Division of Urology</orgName><orgName type="institution">University of Maryland School of Medicine</orgName><address><addrLine>Baltimore</addrLine><addrLine>Maryland</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">James A.</forename><surname>Kodak</surname></persName><affiliation><orgName type="department">Division of Urology</orgName><orgName type="institution">University of Maryland School of Medicine</orgName><address><addrLine>Baltimore</addrLine><addrLine>Maryland</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Arthur A.</forename><surname>Vandenbark</surname></persName><affiliation><orgName type="department">Department of Neuroimmunology</orgName><orgName type="institution">Portland VA Medical Center</orgName><orgName type="department">Portland Oregon and Departments of Neurology</orgName><orgName type="department">and Molecular Microbiology & Immunology</orgName><orgName type="institution">Oregon Health & Science University</orgName><address><addrLine>Portland</addrLine><addrLine>Oregon</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Richard B.</forename><surname>Alexander</surname></persName><affiliation><orgName type="department">Division of Urology</orgName><orgName type="institution">University of Maryland School of Medicine</orgName><address><addrLine>Baltimore</addrLine><addrLine>Maryland</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation><affiliation><address><addrLine>VA Maryland Health Care System</addrLine><addrLine>Baltimore, Maryland</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">58907371FB3DF76E502B7154DBD5BB13126E1297</idno><idno type="ark">ark:/67375/WNG-5HZVGH2P-B</idno><idno type="DOI">10.1002/pros.20575</idno><idno type="unit">PROS20575</idno><idno type="toTypesetVersion">file:PROS.PROS20575.pdf</idno></analytic><monogr><title level="j" type="main">The Prostate</title><title level="j" type="alt">PROSTATE, THE</title><idno type="pISSN">0270-4137</idno><idno type="eISSN">1097-0045</idno><idno type="book-DOI">10.1002/(ISSN)1097-0045</idno><idno type="book-part-DOI">10.1002/pros.v67:10</idno><idno type="product">PROS</idno><imprint><biblScope unit="vol">67</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1019">1019</biblScope><biblScope unit="page" to="1028">1028</biblScope><biblScope unit="page-count">10</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-01"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><head>BACKGROUND</head><p>The crucial role of CD4 T‐cells in anti‐tumor immune response is widely recognized, yet the identification of HLA class II‐restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T‐cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen <hi rend="italic">(HLA)‐DRB1*1501</hi>, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy.</p><head>METHODS</head><p>We immunized transgenic (tg) mice engineered to express <hi rend="italic">HLA‐DRB1*1501</hi> with human PAP. A library of overlapping 20‐mer peptides spanning the entire human PAP sequence was screened <hi rend="italic">in vitro</hi> for T‐cell recognition by proliferative and interferon (IFN)‐γ enzyme‐linked immunosorbent spot (ELISPOT) assays.</p><head>RESULTS</head><p>We identified two 20‐mer peptides, PAP (133–152), and PAP (173–192), that were immunogenic and naturally processed from whole PAP in <hi rend="italic">HLA‐DRB1*1501</hi> tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from <hi rend="italic">HLA‐DRB1*1501</hi>‐positive patients with GP and normal donors.</p><head>CONCLUSIONS</head><p>These peptides can be used for the design of a new generation of peptide‐based vaccines against prostate cancer. The study can also be helpful in understanding the role of autoimmunity in the development of some forms of chronic prostatitis. Prostate 67: 1019–1028, 2007. © 2007 Wiley‐Liss, Inc.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">CD4 T lymphocytes</term><term xml:id="kwd2">DR2 transgenic mice</term><term xml:id="kwd3">HLA‐DR15</term><term xml:id="kwd4">prostate cancer</term><term xml:id="kwd5">prostatitis</term></keywords><keywords rend="articleCategory"><term>Original Article</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-5HZVGH2P-B/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1097-0045</doi><issn type="print">0270-4137</issn><issn type="electronic">1097-0045</issn><idGroup><id type="product" value="PROS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PROSTATE, THE">The Prostate</title><title type="short">Prostate</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/pros.v67:10</doi><numberingGroup><numbering type="journalVolume" number="67">67</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2007-07-01">1 July 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="20" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pros.20575</doi><idGroup><id type="unit" value="PROS20575"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2007 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptReceived" date="2006-11-21"></event><event type="manuscriptAccepted" date="2007-01-31"></event><event type="publishedOnlineEarlyUnpaginated" date="2007-04-23"></event><event type="firstOnline" date="2007-04-23"></event><event type="publishedOnlineFinalForm" date="2007-05-18"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-02"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst">1019</numbering><numbering type="pageLast">1028</numbering></numberingGroup><correspondenceTo>University of Maryland School of Medicine, Department of Surgery, 10 S. Pine Street, MSTF, Room 4‐00A, Baltimore, MD 21201.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:PROS.PROS20575.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="49"></count><count type="wordTotal" number="1468"></count></countGroup><titleGroup><title type="main" xml:lang="en">Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title><title type="short" xml:lang="en">HLA‐DRB1*1501‐Restricted CD4 T‐Cell Epitopes From Human PAP</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Elena N.</givenNames><familyName>Klyushnenkova</familyName></personName><contactDetails><email>eklyushnenkova@smail.umaryland.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Diana V.</givenNames><familyName>Kouiavskaia</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>James A.</givenNames><familyName>Kodak</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Arthur A.</givenNames><familyName>Vandenbark</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Richard B.</givenNames><familyName>Alexander</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>VA Maryland Health Care System, Baltimore, Maryland</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neuroimmunology, Portland VA Medical Center, Portland Oregon and Departments of Neurology, and Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">CD4 T lymphocytes</keyword><keyword xml:id="kwd2">DR2 transgenic mice</keyword><keyword xml:id="kwd3">HLA‐DR15</keyword><keyword xml:id="kwd4">prostate cancer</keyword><keyword xml:id="kwd5">prostatitis</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">BACKGROUND</title><p>The crucial role of CD4 T‐cells in anti‐tumor immune response is widely recognized, yet the identification of HLA class II‐restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T‐cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen <i>(HLA)‐DRB1*1501</i>, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy.</p></section><section xml:id="abs1-2"><title type="main">METHODS</title><p>We immunized transgenic (tg) mice engineered to express <i>HLA‐DRB1*1501</i> with human PAP. A library of overlapping 20‐mer peptides spanning the entire human PAP sequence was screened <i>in vitro</i> for T‐cell recognition by proliferative and interferon (IFN)‐γ enzyme‐linked immunosorbent spot (ELISPOT) assays.</p></section><section xml:id="abs1-3"><title type="main">RESULTS</title><p>We identified two 20‐mer peptides, PAP (133–152), and PAP (173–192), that were immunogenic and naturally processed from whole PAP in <i>HLA‐DRB1*1501</i> tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from <i>HLA‐DRB1*1501</i>‐positive patients with GP and normal donors.</p></section><section xml:id="abs1-4"><title type="main">CONCLUSIONS</title><p>These peptides can be used for the design of a new generation of peptide‐based vaccines against prostate cancer. The study can also be helpful in understanding the role of autoimmunity in the development of some forms of chronic prostatitis. Prostate 67: 1019–1028, 2007. © 2007 Wiley‐Liss, Inc.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>HLA‐DRB1*1501‐Restricted CD4 T‐Cell Epitopes From Human PAP</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase</title></titleInfo><name type="personal"><namePart type="given">Elena N.</namePart><namePart type="family">Klyushnenkova</namePart><affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</affiliation><affiliation>VA Maryland Health Care System, Baltimore, Maryland</affiliation><affiliation>E-mail: eklyushnenkova@smail.umaryland.edu</affiliation><affiliation>Correspondence address: University of Maryland School of Medicine, Department of Surgery, 10 S. Pine Street, MSTF, Room 4‐00A, Baltimore, MD 21201.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Diana V.</namePart><namePart type="family">Kouiavskaia</namePart><affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">James A.</namePart><namePart type="family">Kodak</namePart><affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Arthur A.</namePart><namePart type="family">Vandenbark</namePart><affiliation>Department of Neuroimmunology, Portland VA Medical Center, Portland Oregon and Departments of Neurology, and Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard B.</namePart><namePart type="family">Alexander</namePart><affiliation>Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland</affiliation><affiliation>VA Maryland Health Care System, Baltimore, Maryland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-07-01</dateIssued><dateCaptured encoding="w3cdtf">2006-11-21</dateCaptured><dateValid encoding="w3cdtf">2007-01-31</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">6</extent><extent unit="tables">1</extent><extent unit="references">49</extent><extent unit="words">1468</extent></physicalDescription><abstract lang="en">BACKGROUND: The crucial role of CD4 T‐cells in anti‐tumor immune response is widely recognized, yet the identification of HLA class II‐restricted epitopes derived from tumor antigens has lagged behind compared to class I epitopes. This is particularly true for prostate cancer. Based on the hypothesis that successful cancer immunotherapy will likely resemble autoimmunity, we searched for the CD4 T‐cell epitopes derived from prostatic proteins that are restricted by human leukocyte antigen (HLA)‐DRB1*1501, an allele associated with granulomatous prostatitis (GP), a disease that may have an autoimmune etiology. One of the antigens implicated in the development of autoimmunity in the prostate is prostatic acid phosphatase (PAP), which is also considered a promising target for prostate cancer immunotherapy. METHODS: We immunized transgenic (tg) mice engineered to express HLA‐DRB1*1501 with human PAP. A library of overlapping 20‐mer peptides spanning the entire human PAP sequence was screened in vitro for T‐cell recognition by proliferative and interferon (IFN)‐γ enzyme‐linked immunosorbent spot (ELISPOT) assays. RESULTS: We identified two 20‐mer peptides, PAP (133–152), and PAP (173–192), that were immunogenic and naturally processed from whole PAP in HLA‐DRB1*1501 tg mice. These peptides were also capable of stimulating CD4 T lymphocytes from HLA‐DRB1*1501‐positive patients with GP and normal donors. CONCLUSIONS: These peptides can be used for the design of a new generation of peptide‐based vaccines against prostate cancer. The study can also be helpful in understanding the role of autoimmunity in the development of some forms of chronic prostatitis. Prostate 67: 1019–1028, 2007. © 2007 Wiley‐Liss, Inc.</abstract><subject lang="en"><genre>keywords</genre><topic>CD4 T lymphocytes</topic><topic>DR2 transgenic mice</topic><topic>HLA‐DR15</topic><topic>prostate cancer</topic><topic>prostatitis</topic></subject><relatedItem type="host"><titleInfo><title>The Prostate</title></titleInfo><titleInfo type="abbreviated"><title>Prostate</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Original Article</topic><topic>Original Articles</topic></subject><identifier type="ISSN">0270-4137</identifier><identifier type="eISSN">1097-0045</identifier><identifier type="DOI">10.1002/(ISSN)1097-0045</identifier><identifier type="PublisherID">PROS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1019</start><end>1028</end><total>10</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Clinical use of tumor markers in oncology</title></titleInfo><name type="personal"><namePart type="given">EL</namePart><namePart type="family">Jacobs</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Haskell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer 1991; 15: 299–360.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>299</start><end>360</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Probl Cancer</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>299</start><end>360</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Target molecules in specific immunotherapy against prostate cancer</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Harada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Noguchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Itoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harada M Noguchi M Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 2003; 8: 193–199.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>193</start><end>199</end></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Oncol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>193</start><end>199</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Pilot study of an HLA‐A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant</title></titleInfo><name type="personal"><namePart type="given">DG</namePart><namePart type="family">McNeel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Knutson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Schiffman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DR</namePart><namePart type="family">Davis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Caron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Disis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML. Pilot study of an HLA‐A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 2003; 23: 62–72.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>62</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Immunol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>62</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Phase I clinical trial of a HER‐2/neu peptide (E75) vaccine for the prevention of prostate‐specific antigen recurrence in high‐risk prostate cancer patients</title></titleInfo><name type="personal"><namePart type="given">MT</namePart><namePart type="family">Hueman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZA</namePart><namePart type="family">Dehqanzada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TE</namePart><namePart type="family">Novak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Gurney</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MM</namePart><namePart type="family">Woll</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GB</namePart><namePart type="family">Ryan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CE</namePart><namePart type="family">Storrer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Fisher</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DG</namePart><namePart type="family">McLeod</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CG</namePart><namePart type="family">Ioannides</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ponniah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GE</namePart><namePart type="family">Peoples</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE. Phase I clinical trial of a HER‐2/neu peptide (E75) vaccine for the prevention of prostate‐specific antigen recurrence in high‐risk prostate cancer patients. Clin Cancer Res 2005; 11: 7470–7479.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>7470</start><end>7479</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Cancer Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>7470</start><end>7479</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Induction of specific T‐cell immunity in patients with prostate cancer by vaccination with PSA146‐154 peptide</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Perambakam</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Hallmeyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Reddy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Mahmud</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Bressler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">DeChristopher</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Mahmud</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Nunez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Sosman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Peace</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, Mahmud D, Nunez R, Sosman JA, Peace DJ. Induction of specific T‐cell immunity in patients with prostate cancer by vaccination with PSA146‐154 peptide. Cancer Immunol Immunother 2006; 55: 1033–1042.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>1033</start><end>1042</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Immunol Immunother</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>1033</start><end>1042</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Fuessel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Meye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schmitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Zastrow</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Linne</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Richter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Lobel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">OW</namePart><namePart type="family">Hakenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Hoelig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EP</namePart><namePart type="family">Rieber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Wirth</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fuessel S, Meye A, Schmitz M, Zastrow S, Linne C, Richter K, Lobel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial. Prostate 2006; 66: 811–821.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>811</start><end>821</end></extent></part><relatedItem type="host"><titleInfo><title>Prostate</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>811</start><end>821</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Noguchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Itoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Suekane</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Suetsugu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Katagiri</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yamada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Yamana</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Noda</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S. Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer. Cancer Sci 2004; 95: 77–84.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>77</start><end>84</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Sci</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>77</start><end>84</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Murphy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Tjoa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ragde</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kenny</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Boynton</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen. Prostate 1996; 29: 371–380.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>371</start><end>380</end></extent></part><relatedItem type="host"><titleInfo><title>Prostate</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>371</start><end>380</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>ProPred: Prediction of HLA‐DR binding sites</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Singh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GP</namePart><namePart type="family">Raghava</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Singh H, Raghava GP. ProPred: Prediction of HLA‐DR binding sites. Bioinformatics 2001; 17: 1236–1237.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>1236</start><end>1237</end></extent></part><relatedItem type="host"><titleInfo><title>Bioinformatics</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>1236</start><end>1237</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>A sequence pattern common to T‐cell epitopes</title></titleInfo><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Rothbard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WR</namePart><namePart type="family">Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rothbard JB, Taylor WR. A sequence pattern common to T‐cell epitopes. EMBO J 1988; 7: 93–100.</note><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>93</start><end>100</end></extent></part><relatedItem type="host"><titleInfo><title>EMBO J</title></titleInfo><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>93</start><end>100</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Developing and maintaining protective CD8+ memory T‐cells</title></titleInfo><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Williams</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Holmes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Sun</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Bevan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Williams MA, Holmes BJ, Sun JC, Bevan MJ. Developing and maintaining protective CD8+ memory T‐cells. Immunol Rev 2006; 211: 146–153.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>146</start><end>153</end></extent></part><relatedItem type="host"><titleInfo><title>Immunol Rev</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>146</start><end>153</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Cognate CD4(+) T‐cell licensing of dendritic cells in CD8(+) T‐cell immunity</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NS</namePart><namePart type="family">Wilson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Waithman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Villadangos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FR</namePart><namePart type="family">Carbone</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WR</namePart><namePart type="family">Heath</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GT</namePart><namePart type="family">Belz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT. Cognate CD4(+) T‐cell licensing of dendritic cells in CD8(+) T‐cell immunity. Nat Immunol 2004; 5: 1143–1148.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1143</start><end>1148</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Immunol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1143</start><end>1148</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Tumor‐specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T‐cells against the autologous tumor</title></titleInfo><name type="personal"><namePart type="given">CN</namePart><namePart type="family">Baxevanis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IF</namePart><namePart type="family">Voutsas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">OE</namePart><namePart type="family">Tsitsilonis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Gritzapis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Sotiriadou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Papamichail</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor‐specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T‐cells against the autologous tumor. J Immunol 2000; 164: 3902–3912.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>3902</start><end>3912</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>3902</start><end>3912</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Cutting edge: CD4+ T‐cell control of CD8+ T‐cell reactivity to a model tumor antigen</title></titleInfo><name type="personal"><namePart type="given">DR</namePart><namePart type="family">Surman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Dudley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WW</namePart><namePart type="family">Overwijk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NP</namePart><namePart type="family">Restifo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T‐cell control of CD8+ T‐cell reactivity to a model tumor antigen. J Immunol 2000; 164: 562–565.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>562</start><end>565</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>562</start><end>565</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma</title></titleInfo><name type="personal"><namePart type="given">PD</namePart><namePart type="family">Boasberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Hoon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LD</namePart><namePart type="family">Piro</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Martin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Fujimoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TS</namePart><namePart type="family">Kristedja</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Bhachu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Ye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RR</namePart><namePart type="family">Deck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">O'day</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'day SJ. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658–2663.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>126</number></detail><extent unit="pages"><start>2658</start><end>2663</end></extent></part><relatedItem type="host"><titleInfo><title>J Invest Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>126</number></detail><extent unit="pages"><start>2658</start><end>2663</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy</title></titleInfo><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Rosenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DE</namePart><namePart type="family">White</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rosenberg SA, White DE. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996; 19: 81–84.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>81</start><end>84</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunother</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>81</start><end>84</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Humanized animal models for autoimmune diseases</title></titleInfo><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Gregersen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Holmes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fugger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gregersen JW, Holmes S, Fugger L. Humanized animal models for autoimmune diseases. Tissue Antigens 2004; 63: 383–394.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>383</start><end>394</end></extent></part><relatedItem type="host"><titleInfo><title>Tissue Antigens</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>383</start><end>394</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes</title></titleInfo><name type="personal"><namePart type="given">WW</namePart><namePart type="family">Overwijk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DR</namePart><namePart type="family">Surman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KR</namePart><namePart type="family">Irvine</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CE</namePart><namePart type="family">Touloukian</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CC</namePart><namePart type="family">Chan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MW</namePart><namePart type="family">Carroll</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Moss</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Rosenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NP</namePart><namePart type="family">Restifo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 1999; 96: 2982–2987.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>2982</start><end>2987</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci U S A</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>2982</start><end>2987</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>The clinical spectrum of granulomatous prostatitis: A report of 200 cases</title></titleInfo><name type="personal"><namePart type="given">TJ</namePart><namePart type="family">Stillwell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DE</namePart><namePart type="family">Engen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GM</namePart><namePart type="family">Farrow</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stillwell TJ, Engen DE, Farrow GM. The clinical spectrum of granulomatous prostatitis: A report of 200 cases. J Urol 1987; 138: 320–323.</note><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><extent unit="pages"><start>320</start><end>323</end></extent></part><relatedItem type="host"><titleInfo><title>J Urol</title></titleInfo><part><date>1987</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><extent unit="pages"><start>320</start><end>323</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Granulomatous prostatitis linked to HLA‐DRB1*1501</title></titleInfo><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Alexander</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Mann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Borkowski</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Fernandez‐Vina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EN</namePart><namePart type="family">Klyushnenkova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kodak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KJ</namePart><namePart type="family">Propert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Kincaid</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alexander RB, Mann DL, Borkowski AA, Fernandez‐Vina M, Klyushnenkova EN, Kodak J, Propert KJ, Kincaid M. Granulomatous prostatitis linked to HLA‐DRB1*1501. J Urol 2004; 171: 2326–2329.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>171</number></detail><extent unit="pages"><start>2326</start><end>2329</end></extent></part><relatedItem type="host"><titleInfo><title>J Urol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>171</number></detail><extent unit="pages"><start>2326</start><end>2329</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Multiple sclerosis: MHC associations and therapeutic implications</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Holmes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Siebold</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EY</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Friese</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fugger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Bell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holmes S, Siebold C, Jones EY, Friese MA, Fugger L, Bell J. Multiple sclerosis: MHC associations and therapeutic implications. Expert Rev Mol Med 2005; 7: 1–17.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1</start><end>17</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev Mol Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1</start><end>17</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>CD4 and CD8 T‐lymphocyte recognition of prostate specific antigen in granulomatous prostatitis</title></titleInfo><name type="personal"><namePart type="given">EN</namePart><namePart type="family">Klyushnenkova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ponniah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Rodriguez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kodak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DL</namePart><namePart type="family">Mann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Langerman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MI</namePart><namePart type="family">Nishimura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Alexander</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Klyushnenkova EN, Ponniah S, Rodriguez A, Kodak J, Mann DL, Langerman A, Nishimura MI, Alexander RB. CD4 and CD8 T‐lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother 2004; 27: 136–146.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>136</start><end>146</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunother</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>136</start><end>146</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from prostate‐specific antigen</title></titleInfo><name type="personal"><namePart type="given">EN</namePart><namePart type="family">Klyushnenkova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Link</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WT</namePart><namePart type="family">Oberle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kodak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Rich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Vandenbark</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Alexander</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Klyushnenkova EN, Link J, Oberle WT, Kodak J, Rich C, Vandenbark AA, Alexander RB. Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from prostate‐specific antigen. Clin Cancer Res 2005; 11: 2853–2861.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>2853</start><end>2861</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Cancer Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>2853</start><end>2861</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Human major histocompatibility complex class II‐restricted T‐cell responses in transgenic mice</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Woods</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HY</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Trumbauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Sirotina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Cummings</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Zaller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Woods A, Chen HY, Trumbauer ME, Sirotina A, Cummings R, Zaller DM. Human major histocompatibility complex class II‐restricted T‐cell responses in transgenic mice. J Exp Med 1994; 180: 173–181.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>180</number></detail><extent unit="pages"><start>173</start><end>181</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>180</number></detail><extent unit="pages"><start>173</start><end>181</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35‐55peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA‐DR2 transgenic mice</title></titleInfo><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Vandenbark</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Rich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Mooney</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Zamora</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Huan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fugger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Offner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GG</namePart><namePart type="family">Burrows</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, Huan J, Fugger L, Offner H, Jones R, Burrows GG. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35‐55peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA‐DR2 transgenic mice. J Immunol 2003; 171: 127–133.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>171</number></detail><extent unit="pages"><start>127</start><end>133</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>171</number></detail><extent unit="pages"><start>127</start><end>133</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Myelin oligodendrocyte glycoprotein‐ 35‐55peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA‐DR2‐transgenic mice</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Rich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Link</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Zamora</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Jacobsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Meza‐Romero</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Offner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GG</namePart><namePart type="family">Burrows</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fugger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AA</namePart><namePart type="family">Vandenbark</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rich C, Link JM, Zamora A, Jacobsen H, Meza‐Romero R, Offner H, Jones R, Burrows GG, Fugger L, Vandenbark AA. Myelin oligodendrocyte glycoprotein‐ 35‐55peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA‐DR2‐transgenic mice. Eur J Immunol 2004; 34: 1251–1261.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1251</start><end>1261</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Immunol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1251</start><end>1261</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Kovats</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Drover</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WH</namePart><namePart type="family">Marshall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Freed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PE</namePart><namePart type="family">Whiteley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GT</namePart><namePart type="family">Nepom</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Blum</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kovats S, Drover S, Marshall WH, Freed D, Whiteley PE, Nepom GT, Blum JS. Coordinate defects in human histocompatibility leukocyte antigen class II expression and antigen presentation in bare lymphocyte syndrome. J Exp Med 1994; 179: 2017–2022.</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>179</number></detail><extent unit="pages"><start>2017</start><end>2022</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>179</number></detail><extent unit="pages"><start>2017</start><end>2022</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA‐A2402 binding peptide</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Inoue</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Takaue</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Takei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kato</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Kanai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Harada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Tobisu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Noguchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kakizoe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Itoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Wakasugi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y, Tobisu K, Noguchi M, Kakizoe T, Itoh K, Wakasugi H. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA‐A2402 binding peptide. J Urol 2001; 166: 1508–1513.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>1508</start><end>1513</end></extent></part><relatedItem type="host"><titleInfo><title>J Urol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>1508</start><end>1513</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Preventive and therapeutic vaccination with PAP‐3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Machlenkin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Azriel‐Rosenfeld</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Volovitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Vadai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Lev</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Paz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Goldberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Reiter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Tzehoval</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Benhar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Eisenbach</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Machlenkin A, Azriel‐Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L. Preventive and therapeutic vaccination with PAP‐3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother 2007; 56: 217–226.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>217</start><end>226</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Immunol Immunother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>217</start><end>226</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Identification of peptide vaccine candidates for prostate cancer patients with HLA‐A3 supertype alleles</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Matsueda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Takedatsu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Tanaka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Noguchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Itoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Harada</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, Harada M. Identification of peptide vaccine candidates for prostate cancer patients with HLA‐A3 supertype alleles. Clin Cancer Res 2005; 11: 6933–6943.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>6933</start><end>6943</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Cancer Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>6933</start><end>6943</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Induction of prostate tumor‐specific CD8+ cytotoxic T‐lymphocytes in vitro using antigen‐presenting cells pulsed with prostatic acid phosphatase peptide</title></titleInfo><name type="personal"><namePart type="given">MV</namePart><namePart type="family">Peshwa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Ruegg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Laus</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WC</namePart><namePart type="family">van Schooten</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor‐specific CD8+ cytotoxic T‐lymphocytes in vitro using antigen‐presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36: 129–138.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>129</start><end>138</end></extent></part><relatedItem type="host"><titleInfo><title>Prostate</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>129</start><end>138</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Specific stimulation of MHC‐transgenic mouse T‐cell hybridomas with xenogeneic APC</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Vidovic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TJ</namePart><namePart type="family">Graddis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LP</namePart><namePart type="family">Stepan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Zaller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Laus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vidovic D, Graddis TJ, Stepan LP, Zaller DM, Laus R. Specific stimulation of MHC‐transgenic mouse T‐cell hybridomas with xenogeneic APC. Hum Immunol 2003; 64: 238–244.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>238</start><end>244</end></extent></part><relatedItem type="host"><titleInfo><title>Hum Immunol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>238</start><end>244</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>Identification of T helper epitopes from prostatic acid phosphatase</title></titleInfo><name type="personal"><namePart type="given">DG</namePart><namePart type="family">McNeel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LD</namePart><namePart type="family">Nguyen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Disis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McNeel DG, Nguyen LD, Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 2001; 61: 5161–5167.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>5161</start><end>5167</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Res</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>5161</start><end>5167</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Induction of tissue‐specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CL</namePart><namePart type="family">Ruegg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Brockstedt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EG</namePart><namePart type="family">Engleman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Laus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue‐specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer. J Immunol 1997; 159: 3113–3117.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>159</number></detail><extent unit="pages"><start>3113</start><end>3117</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>159</number></detail><extent unit="pages"><start>3113</start><end>3117</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)</title></titleInfo><name type="personal"><namePart type="given">LE</namePart><namePart type="family">Johnson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TP</namePart><namePart type="family">Frye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AR</namePart><namePart type="family">Arnot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Marquette</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LA</namePart><namePart type="family">Couture</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Gendron‐Fitzpatrick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DG</namePart><namePart type="family">McNeel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron‐Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006; 24: 293–303.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>293</start><end>303</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>293</start><end>303</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Immunization of Lewis rats with a prostate cancer xenoantigen elicits predominantly xenoantigen epitope‐specific T‐cell responses</title></titleInfo><name type="personal"><namePart type="given">LE</namePart><namePart type="family">Johnson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TP</namePart><namePart type="family">Frye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DG</namePart><namePart type="family">McNeel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Johnson LE, Frye TP, McNeel DG. Immunization of Lewis rats with a prostate cancer xenoantigen elicits predominantly xenoantigen epitope‐specific T‐cell responses. Proc Am Assoc Cancer Res 2006; 47: 1174 (Abstract).</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1174</start></extent></part><relatedItem type="host"><titleInfo><title>Proc Am Assoc Cancer Res</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1174</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Qin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Ma</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Liang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunol Lett 2005; 99: 85–93.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>85</start><end>93</end></extent></part><relatedItem type="host"><titleInfo><title>Immunol Lett</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>85</start><end>93</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Autoimmune prostatitis: Evidence of T‐cell reactivity with normal prostatic proteins</title></titleInfo><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Alexander</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Brady</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ponniah</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: Evidence of T‐cell reactivity with normal prostatic proteins. Urology 1997; 50: 893–899.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>893</start><end>899</end></extent></part><relatedItem type="host"><titleInfo><title>Urology</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>893</start><end>899</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Three predominant proteins secreted by the human prostate gland</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Lilja</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Abrahamsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988; 12: 29–38.</note><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>29</start><end>38</end></extent></part><relatedItem type="host"><titleInfo><title>Prostate</title></titleInfo><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>29</start><end>38</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>PSA is a candidate self‐antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ponniah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Arah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Alexander</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ponniah S, Arah I, Alexander RB. PSA is a candidate self‐antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000; 44: 49–54.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>49</start><end>54</end></extent></part><relatedItem type="host"><titleInfo><title>Prostate</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>49</start><end>54</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Presence of INFgamma‐secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients</title></titleInfo><name type="personal"><namePart type="given">RD</namePart><namePart type="family">Motrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Maccioni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Molina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tissera</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Olmedo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Riera</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VE</namePart><namePart type="family">Rivero</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Motrich RD, Maccioni M, Molina R, Tissera A, Olmedo J, Riera CM, Rivero VE. Presence of INFgamma‐secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol 2005; 116: 149–157.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>149</start><end>157</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>149</start><end>157</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Organ specific autoantigens and the autoreactiveT‐cell repertoire: The case of myelin oligodendrocyte glycoprotein</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Wekerle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Linington</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wekerle H, Linington C. Organ specific autoantigens and the autoreactiveT‐cell repertoire: The case of myelin oligodendrocyte glycoprotein. Eur J Immunol 2006; 36: 512–515.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>512</start><end>515</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Immunol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>512</start><end>515</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>From vanilla to 28 flavors: Multiple varieties of T regulatory cells</title></titleInfo><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Shevach</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shevach EM. From vanilla to 28 flavors: Multiple varieties of T regulatory cells. Immunity 2006; 25: 195–201.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>195</start><end>201</end></extent></part><relatedItem type="host"><titleInfo><title>Immunity</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>195</start><end>201</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Immunotherapy for prostate cancer</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Small</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep 2006; 7: 239–246.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>239</start><end>246</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Urol Rep</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>239</start><end>246</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells</title></titleInfo><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Hershberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Small</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 2006; 24: 434–441.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>434</start><end>441</end></extent></part><relatedItem type="host"><titleInfo><title>Urol Oncol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>434</start><end>441</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Dendritic cell‐based xenoantigen vaccination for prostate cancer immunotherapy</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Fong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Brockstedt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Benike</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JK</namePart><namePart type="family">Breen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Strang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CL</namePart><namePart type="family">Ruegg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EG</namePart><namePart type="family">Engleman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG. Dendritic cell‐based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167: 7150–7156.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>167</number></detail><extent unit="pages"><start>7150</start><end>7156</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>167</number></detail><extent unit="pages"><start>7150</start><end>7156</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>Prostate‐related antigen‐derived new peptides having the capacity of inducing prostate cancer‐reactive CTLs in HLA‐A2+ prostate cancer patients</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Harada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Matsueda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Yao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ogata</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Noguchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Itoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Prostate‐related antigen‐derived new peptides having the capacity of inducing prostate cancer‐reactive CTLs in HLA‐A2+ prostate cancer patients. Oncol Rep 2004; 12: 601–607.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>601</start><end>607</end></extent></part><relatedItem type="host"><titleInfo><title>Oncol Rep</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>601</start><end>607</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Dendritic cell‐based multi‐epitope immunotherapy of hormone‐refractory prostate carcinoma</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Waeckerle‐Men</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Uetz‐von Allmen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Fopp</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">von Moos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Bohme</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HP</namePart><namePart type="family">Schmid</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Ackermann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Cerny</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Ludewig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Groettrup</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Gillessen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Waeckerle‐Men Y, Uetz‐von Allmen E, Fopp M, von Moos R, Bohme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S. Dendritic cell‐based multi‐epitope immunotherapy of hormone‐refractory prostate carcinoma. Cancer Immunol Immunother 2006; 55: 1524–1533.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>1524</start><end>1533</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Immunol Immunother</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>1524</start><end>1533</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Kramer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Mitteregger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Marberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kramer G, Mitteregger D, Marberger M. Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease. Eur Urol 2007; 51: 1202–1216.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>1202</start><end>1216</end></extent></part><relatedItem type="host"><titleInfo><title>Eur Urol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>1202</start><end>1216</end></extent></part></relatedItem></relatedItem><identifier type="istex">58907371FB3DF76E502B7154DBD5BB13126E1297</identifier><identifier type="ark">ark:/67375/WNG-5HZVGH2P-B</identifier><identifier type="DOI">10.1002/pros.20575</identifier><identifier type="ArticleID">PROS20575</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-5HZVGH2P-B/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001B06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:58907371FB3DF76E502B7154DBD5BB13126E1297
|texte= Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase
}}
| This area was generated with Dilib version V0.6.33. |  |